Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri,Rohit Loomba,Arun J. Sanyal,Joel E. Lavine,Mark L. Van Natta,Manal F. Abdelmalek,Naga Chalasani,Srinivasan Dasarathy,Anna Mae Diehl,Bilal Hameed,Kris V. Kowdley,Arthur J. McCullough,Norah A. Terrault,Jeanne M. Clark,James Tonascia,Elizabeth M. Brunt,David E. Kleiner,Edward Doo +17 more
Reads0
Chats0
TLDR
Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification.About:
This article is published in The Lancet.The article was published on 2015-03-14 and is currently open access. It has received 1798 citations till now. The article focuses on the topics: Obeticholic acid & Fatty liver.read more
Citations
More filters
Journal ArticleDOI
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani,Zobair M. Younossi,Joel E. Lavine,Michael Charlton,Kenneth Cusi,Mary E. Rinella,Stephen A. Harrison,Elizabeth M. Brunt,Arun J. Sanyal +8 more
TL;DR: This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care.
Journal ArticleDOI
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
Giulio Marchesini,Christopher P. Day,Jean-François Dufour,Ali Canbay,Valerio Nobili,Vlad Ratziu,Herbert Tilg,Michael Roden,Amalia Gastaldelli,Hannele Yki-Järvinen,Fritz Schick,Roberto Vettor,Gema Frühbeck,Lisbeth Mathus-Vliegen +13 more
TL;DR: The final purpose is to improve patient care and awareness of the importance of NAFLD, and to assist stakeholders in the decision-making process by providing evidence-based data, which also takes into consideration the burden of clinical management for the healthcare system.
Journal ArticleDOI
Mechanisms of NAFLD development and therapeutic strategies
TL;DR: Understanding of pathogenic mechanisms and clinical features of NAFLD is driving progress in therapeutic strategies now in clinical trials and the emerging targets for drug development that involve either single agents or combination therapies intended to arrest or reverse disease progression are discussed.
Journal ArticleDOI
Type 2 diabetes mellitus.
Ralph A. DeFronzo,Ele Ferrannini,Leif Groop,Robert R. Henry,William H. Herman,Jens J. Holst,Frank B. Hu,C. Ronald Kahn,Itamar Raz,Gerald I. Shulman,Donald C. Simonson,Marcia A. Testa,Ram Weiss +12 more
TL;DR: The greatest need is for agents that enhance insulin sensitivity, halt the progressive pancreatic β-cell failure that is characteristic of T2DM and prevent or reverse the microvascular complications.
Journal ArticleDOI
Nonalcoholic Fatty Liver Disease: A Systematic Review
TL;DR: How to identify patients with nonalcoholic fatty liver disease at greatest risk of non Alcoholic steatohepatitis and cirrhosis is illustrated and the role and limitations of current diagnostics and liver biopsy are discussed to provide an outline for the management of patients across the spectrum of non alcoholic fatty Liver disease.
References
More filters
Journal ArticleDOI
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
David E. Kleiner,Elizabeth M. Brunt,Mark L. Van Natta,Cynthia Behling,Melissa J. Contos,Oscar W. Cummings,Linda D. Ferrell,Yao Chang Liu,Michael Torbenson,Aynur Unalp-Arida,Matthew M. Yeh,Arthur J. McCullough,Arun J. Sanyal +12 more
TL;DR: A strong scoring system and NAS for NAFLD and NASH with reasonable inter‐rater reproducibility that should be useful for studies of both adults and children with any degree ofNAFLD are presented.
Journal ArticleDOI
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani,Zobair M. Younossi,Joel E. Lavine,Anna Mae Diehl,Elizabeth M. Brunt,Kenneth Cusi,Michael Charlton,Arun J. Sanyal +7 more
TL;DR: This is a practice guideline for clinicians rather than a review article and interested readers can refer to several comprehensive reviews published recently.
Journal ArticleDOI
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal,Naga Chalasani,Kris V. Kowdley,Arthur J. McCullough,Anna Mae Diehl,Nathan M. Bass,Brent A. Neuschwander-Tetri,Joel E. Lavine,James Tonascia,Aynur Unalp,Mark L. Van Natta,Jeanne M. Clark,Elizabeth M. Brunt,David E. Kleiner,Jay H. Hoofnagle,Patricia R. Robuck +15 more
TL;DR: Vitamin E was superior to placebo for the treatment of nonalcoholic steatohepatitis in adults without diabetes, and significant benefits of pioglitazone were observed for some of the secondary outcomes.
Journal ArticleDOI
Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings
Elizabeth M. Brunt,David E. Kleiner,Laura A. Wilson,Patricia Belt,Brent A. Neuschwander-Tetri +4 more
TL;DR: The diagnosis of definite steatohepatitis or the absence of SH based on evaluation of patterns as well as individual lesions on liver biopsies does not always correlate with threshold values of the semiquantitative NAS.
Journal ArticleDOI
Pleiotropic Roles of Bile Acids in Metabolism
TL;DR: This review covers the roles of specific bile acids, synthetic agonists, and their cognate receptors in controlling these diverse functions, as well as their current use in treating human diseases.